Hc45 Hydrocortisone Acetate 1% w/w Cream

  • Name:

    Hc45 Hydrocortisone Acetate 1% w/w Cream

  • Company:
    info
  • Active Ingredients:

    Hydrocortisone Acetate

  • Legal Category:

    Supply through pharmacy only

Summary of Product Characteristics last updated on medicines.ie: 3/12/2015
print

Print ViewKeyword Search SmPC

Reckitt Benckiser Ireland Limited

Reckitt Benckiser Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Bonjela Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Bonjela Teething Gel Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Dettol Antiseptic Disinfectant 4.8 % w/v Concentrate for Cutaneous Solution Active Ingredients Chloroxylenol
Medicine Name Disprin Direct 300mg Orodispersible Tablets Active Ingredients Aspirin
Medicine Name Disprin Extra Strength 500mg Effervescent Tablets Active Ingredients Acetylsalicylic Acid
Medicine Name Disprin Original 300mg Dispersible Tablets Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name E45 Cream Active Ingredients Anhydrous Lanolin, Light Liquid Paraffin, White Soft Paraffin
Medicine Name Fybogel Citrus Active Ingredients Ispaghula Husk
Medicine Name Fybogel Mebeverine Active Ingredients Ispaghula Husk, Mebeverine Hydochloride
Medicine Name Fybogel Orange 3.5g Granules Active Ingredients Ispaghula Husk
Medicine Name Gaviscon Advance Oral Suspension Active Ingredients Potassium hydrogen carbonate, Sodium Alginate
Medicine Name Gaviscon Advance Tablets Active Ingredients Potassium Bicarbonate, Sodium Alginate
Medicine Name Gaviscon Extra Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Oral Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Oral Suspension 300ml Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Infant Active Ingredients Magnesium Alginate, Sodium Alginate
Medicine Name Gaviscon Liquid - Peppermint Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Liquid Aniseed Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Peppermint Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Hydrogen Carbonate
Medicine Name Gaviscon Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Hc45 Hydrocortisone Acetate 1% w/w Cream Active Ingredients Hydrocortisone Acetate
Medicine Name Lemsip Chesty Cough 50 mg/5 ml Oral Solution Active Ingredients Guaifenesin
Medicine Name Lemsip Cold & Flu Capsules with Caffeine Active Ingredients Caffeine, Paracetamol
Medicine Name Lemsip Cold & Flu Headcold 500mg Powder for Oral Solution Active Ingredients Paracetamol
Medicine Name Lemsip Cold & Flu Hot Lemon 500mg Powder for Oral Solution Active Ingredients Paracetamol
1 - 0 of 64 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 3 December 2015 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

4.2  Posology and Method of Administration

 

Adults and children over 10 years:, Once or twice a day, for a maximum of 7 days.

 

Medical advice should be sought if the condition does not improve.

 

Elderly population

Dosage adjustments are not considered necessary in the elderly.

 

Paediatric population

Dosage recommendations as above for children over 10 years of age. The product should not be used in children under 10 years of age unless recommended by a health care professional.

 

Method of administration

For topical administration.

Apply sparingly to a small area. Massage gently into the skin.


4.3 
Contraindications

 

Hypersensitivity to hydrocortisone acetate or to any of the excipients listed in section 6.1

 

Do not use on the eyes or face (for example, in rosacea or perioral dermatoses)  the ano-genital area or on broken or infected skin, (including impetigo, cold sores, acne or athlete’s foot or infected bites or stings).

 

Use in the presence of untreated infections of bacterial, viral, tuberculous or fungal origin.

 

Not for use with an occlusive dressing or on large areas of the body.


4.4  Special Warnings and Special Precautions for Use

 

The product should not be used during pregnancy or breast-feeding unless recommended by a health care professional (see section 4.6).

 

Prolonged use of the product is not recommended (see section 4.2) as continuous application without interruption will result in local atrophy of the skin, striae and superficial vascular dilatation, particularly of the face.

 

Prolonged use of uninterrupted occlusion or use with extensive occlusive dressings may suppress adrenocortical function.

 

This product contains ceteostearly alcohol which my cause local skin reactions (e.g. contact dermatitis).

4.6  Fertility, Pregnancy and Lactation

 

Pregnancy:

 

Should not be used in pregnancy unless considered essential by the physician.  There are no or limited amount of data from the use of topical corticosteroids in pregnant women. Studies in animals have shown reproductive toxicity. 

Breast-feeding

The product should not be used whilst breast-feeding unless recommended by a health care professional. Corticosteroids are excreted in human milk. A risk to new-borns/infants cannot be excluded.

Fertility

No known effects.

                            
                            4.8 Undesirable Effects
                        

 

As hydrocortisone acetate is a weak corticosteroid, topical preparations are usually well tolerated, especially under recommended use, where treatment exposure and duration is restricted (see section 4.2).

 

Undesirable effects from topical corticosteroids are more commonly associated with potent corticosteroids compared with weak agents like hydrocortisone acetate. Adverse effects are very uncommon and typically linked with prolonged therapy or misuse (see section 4.9). If any signs of hypersensitivity, including allergic contact dermatitis or worsening of the original condition appear, treatment should be immediately discontinued.

 

Adverse events which have been associated with topical corticosteroids are given below, tabulated by system organ class and frequency. Frequencies are defined as: Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10,000 and <1/1000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.

 

System Organ Class

Frequency

Adverse Events

Skin and Subcutaneous Tissue Disorders

Not known

Skin atrophy, telangiectasia, skin striae, acne, rosacea, pigmentation disorder, hypertrichosis

Musculoskeletal and Connective Tissue Disorders

Not known

Collagen disorder

 

 

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail:medsafety@hpra.ie

 

4.2  Overdose

 

No special antidotes are likely to be required.

 

Acute overdose is highly unlikely. Chronic overdose or misuse may increase the risk of topical or systemic steroid-related adverse effects, including hypothalamic pituitary adrenal (HPA) axis suppression and Cushing’s syndrome.

 

Management of overdose with topical corticosteroids includes gradual discontinuation under medical supervision.


5.2 
Pharmacodynamic Properties

 

Pharmacotherapeutic Group: Corticosteroids, dermatological preparations; corticosteroids, weak (group I); ATC Code: D07AA02

 

 

Hydrocortisone is a corticosteroid which has anti-inflammatory activity.

 

5.3  Pharmacokinetic Properties

 

Hydrocortisone acetate is a well characterised corticosteroid which has anti-inflammatory activity resulting at least in part, from binding with a steroid receptor.

 

Hydrocortisone acetate reduces inflammation by stabilising cell membranes, preventing the release of destructive enzymes, antagonising histamine and the release of kinins, inhibiting accumulation of macrophages and reducing capillary wall permeability and oedema formation.

 

5.4  Preclinical Safety Data

 

Whilst there is inadequate evidence on safety in human pregnancy, animal studies have demonstrated a possible association between topical corticosteroids and foetal abnormalities, including cleft palate and intra-uterine growth retardation.

 

Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation. Absorption may be markedly increased when the skin has lost its keratin layers and can be increased by inflammation or diseases of the epidermal barrier.

 

Hydrocortisone is absorbed to a greater degree from scrotum, axilla, eyelid, face and scalp than from the forearm, knee, palm and sole.

 

10        DATE OF (PARTIAL) REVISION OF THE TEXT

 

 July 2015

Updated on 3 December 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 3 December 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

4.2  Posology and Method of Administration

 

Adults and children over 10 years:, Once or twice a day, for a maximum of 7 days.

 

Medical advice should be sought if the condition does not improve.

 

Elderly population

Dosage adjustments are not considered necessary in the elderly.

 

Paediatric population

Dosage recommendations as above for children over 10 years of age. The product should not be used in children under 10 years of age unless recommended by a health care professional.

 

Method of administration

For topical administration.

Apply sparingly to a small area. Massage gently into the skin.


4.3 
Contraindications

 

Hypersensitivity to hydrocortisone acetate or to any of the excipients listed in section 6.1

 

Do not use on the eyes or face (for example, in rosacea or perioral dermatoses)  the ano-genital area or on broken or infected skin, (including impetigo, cold sores, acne or athlete’s foot or infected bites or stings).

 

Use in the presence of untreated infections of bacterial, viral, tuberculous or fungal origin.

 

Not for use with an occlusive dressing or on large areas of the body.


4.4  Special Warnings and Special Precautions for Use

 

The product should not be used during pregnancy or breast-feeding unless recommended by a health care professional (see section 4.6).

 

Prolonged use of the product is not recommended (see section 4.2) as continuous application without interruption will result in local atrophy of the skin, striae and superficial vascular dilatation, particularly of the face.

 

Prolonged use of uninterrupted occlusion or use with extensive occlusive dressings may suppress adrenocortical function.

 

This product contains ceteostearly alcohol which my cause local skin reactions (e.g. contact dermatitis).

4.6  Fertility, Pregnancy and Lactation

 

Pregnancy:

 

Should not be used in pregnancy unless considered essential by the physician.  There are no or limited amount of data from the use of topical corticosteroids in pregnant women. Studies in animals have shown reproductive toxicity. 

Breast-feeding

The product should not be used whilst breast-feeding unless recommended by a health care professional. Corticosteroids are excreted in human milk. A risk to new-borns/infants cannot be excluded.

Fertility

No known effects.

                            
                            4.8 Undesirable Effects
                        

 

As hydrocortisone acetate is a weak corticosteroid, topical preparations are usually well tolerated, especially under recommended use, where treatment exposure and duration is restricted (see section 4.2).

 

Undesirable effects from topical corticosteroids are more commonly associated with potent corticosteroids compared with weak agents like hydrocortisone acetate. Adverse effects are very uncommon and typically linked with prolonged therapy or misuse (see section 4.9). If any signs of hypersensitivity, including allergic contact dermatitis or worsening of the original condition appear, treatment should be immediately discontinued.

 

Adverse events which have been associated with topical corticosteroids are given below, tabulated by system organ class and frequency. Frequencies are defined as: Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10,000 and <1/1000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.

 

System Organ Class

Frequency

Adverse Events

Skin and Subcutaneous Tissue Disorders

Not known

Skin atrophy, telangiectasia, skin striae, acne, rosacea, pigmentation disorder, hypertrichosis

Musculoskeletal and Connective Tissue Disorders

Not known

Collagen disorder

 

 

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail:medsafety@hpra.ie

 

4.2  Overdose

 

No special antidotes are likely to be required.

 

Acute overdose is highly unlikely. Chronic overdose or misuse may increase the risk of topical or systemic steroid-related adverse effects, including hypothalamic pituitary adrenal (HPA) axis suppression and Cushing’s syndrome.

 

Management of overdose with topical corticosteroids includes gradual discontinuation under medical supervision.


5.2 
Pharmacodynamic Properties

 

Pharmacotherapeutic Group: Corticosteroids, dermatological preparations; corticosteroids, weak (group I); ATC Code: D07AA02

 

 

Hydrocortisone is a corticosteroid which has anti-inflammatory activity.

 

5.3  Pharmacokinetic Properties

 

Hydrocortisone acetate is a well characterised corticosteroid which has anti-inflammatory activity resulting at least in part, from binding with a steroid receptor.

 

Hydrocortisone acetate reduces inflammation by stabilising cell membranes, preventing the release of destructive enzymes, antagonising histamine and the release of kinins, inhibiting accumulation of macrophages and reducing capillary wall permeability and oedema formation.

 

5.4  Preclinical Safety Data

 

Whilst there is inadequate evidence on safety in human pregnancy, animal studies have demonstrated a possible association between topical corticosteroids and foetal abnormalities, including cleft palate and intra-uterine growth retardation.

 

Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation. Absorption may be markedly increased when the skin has lost its keratin layers and can be increased by inflammation or diseases of the epidermal barrier.

 

Hydrocortisone is absorbed to a greater degree from scrotum, axilla, eyelid, face and scalp than from the forearm, knee, palm and sole.

 

10        DATE OF (PARTIAL) REVISION OF THE TEXT

 

 July 2015

Updated on 5 July 2011 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Free text change information supplied by the pharmaceutical company

Section 4.4 updated to include the statement " This product contains ceteostearly alcohol which may cause local skin reactions (e.g. contact dermatitis).

Updated on 5 July 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.4 updated to include the statement " This product contains ceteostearly alcohol which may cause local skin reactions (e.g. contact dermatitis).

Updated on 4 March 2009 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number

Free text change information supplied by the pharmaceutical company

Update PA Holder to Reckitt Benckiser Ireland Ltd
Update PA Number to 979/45/1

Updated on 4 March 2009 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Update PA Holder to Reckitt Benckiser Ireland Ltd
Update PA Number to 979/45/1

Updated on 13 May 2008 PIL

Reasons for updating

  • Change to section 1 - Name of medicinal product

Free text change information supplied by the pharmaceutical company

Change in trade name of medicinal product.

Updated on 13 May 2008 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Change in trade name of medicinal product.

Updated on 27 August 2007 PIL

Reasons for updating

  • New SPC for medicines.ie

Updated on 27 August 2007 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through pharmacy only